Hannah Rütten1,2, Anke Rissmann3, Birgit Brett4, Serban-Dan Costa2, Birgit Doßow5, Jacqueline Färber6, Stefan Fest7, Christiane Fritzsch8, Anke Lux9, Ilona Päge10, Claudia Spillner1,4, Anke Redlich2. 1. Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke University Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. 2. Department of Obstetrics and Gynaecology, University Hospital Magdeburg, Magdeburg, Germany. 3. Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke University Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. anke.rissmann@med.ovgu.de. 4. Social Paediatrics Centre Magdeburg, Magdeburg, Germany. 5. In-house Doctor Department, University Hospital Magdeburg, Magdeburg, Germany. 6. Department of Microbiology, University Hospital Magdeburg, Magdeburg, Germany. 7. University Children's Hospital Magdeburg, University Hospital Magdeburg, Magdeburg, Germany. 8. Social Paediatrics Centre, St. Elisabeth und St. Barbara Hospital Halle, Halle, Germany. 9. Institute for Biometrics and Medical Informatics, University Magdeburg, Magdeburg, Germany. 10. Department of Clinical Chemistry, University Hospital Magdeburg, Magdeburg, Germany.
Abstract
PURPOSE: This is the first study to determine the cytomegalovirus (CMV) seronegativity rate for women of childbearing age in Saxony-Anhalt and to determine the prevalence of clinically relevant congenital CMV (cCMV) infection in Central Germany, because there are no valid data available. METHODS: The retrospective study was undertaken between January 2005 and December 2015. For the first time in Germany, the following seven data sources were used to analyze the prevalence of clinically relevant cCMV infection and the rate of CMV seronegative women of childbearing age: CMV Screening in maternity unit, University Women's Hospital, Social Paediatrics Centre (SPC), Malformation Monitoring Centre (MMC), Newborn Hearing Screening (NHS), Neonatal Intensive Care Unit (NICU), and In-house Doctor Department. Key parameters were anti-CMV IgG and IgM, CMV PCR of urine, and clinically relevant symptoms caused by CMV. RESULTS: Between 46 and 52% of women of childbearing age were CMV seronegative. The prevalence of clinically relevant cCMV infection was between 0.008 and 0.04%. CONCLUSIONS: The CMV seronegativity rate of women of childbearing age was confirmed to be in the middle range of estimated data from other sources in Germany. Data from the NICU, SPC, NHS, and MMC show the prevalence of clinically relevant cCMV infection. The risk of all cCMV infections is underestimated. Thus, the true prevalence of clinically relevant and subclinical cCMV infections is >0.04%.
PURPOSE: This is the first study to determine the cytomegalovirus (CMV) seronegativity rate for women of childbearing age in Saxony-Anhalt and to determine the prevalence of clinically relevant congenital CMV (cCMV) infection in Central Germany, because there are no valid data available. METHODS: The retrospective study was undertaken between January 2005 and December 2015. For the first time in Germany, the following seven data sources were used to analyze the prevalence of clinically relevant cCMVinfection and the rate of CMV seronegative women of childbearing age: CMV Screening in maternity unit, University Women's Hospital, Social Paediatrics Centre (SPC), Malformation Monitoring Centre (MMC), Newborn Hearing Screening (NHS), Neonatal Intensive Care Unit (NICU), and In-house Doctor Department. Key parameters were anti-CMV IgG and IgM, CMV PCR of urine, and clinically relevant symptoms caused by CMV. RESULTS: Between 46 and 52% of women of childbearing age were CMV seronegative. The prevalence of clinically relevant cCMVinfection was between 0.008 and 0.04%. CONCLUSIONS: The CMV seronegativity rate of women of childbearing age was confirmed to be in the middle range of estimated data from other sources in Germany. Data from the NICU, SPC, NHS, and MMC show the prevalence of clinically relevant cCMVinfection. The risk of all cCMVinfections is underestimated. Thus, the true prevalence of clinically relevant and subclinical cCMVinfections is >0.04%.